Wang Si-Ning, Lu Yi-Zhou, Zhao Yujuan, Cao Wei, Zhang Rui-Li
Department of Dermatology, The Second Affiliated Hospital Nanjing Medical University, Nanjing Medical University, Nanjing, People's Republic of China.
Int Med Case Rep J. 2025 Jan 30;18:205-209. doi: 10.2147/IMCRJ.S503807. eCollection 2025.
Palmoplantar pustulosis (PPP) is a chronic condition characterized by the presence of sterile pustules on the palms and soles of the feet. As we all know, there is currently no gold standard for the treatment of this intractable disease. Currently, interleukin-36 receptor (IL-36R)-targeted biologics are emerging as promising treatments for PPP. Here, we were the first to report a Chinese male with PPP who received an intralesional injection of spesolimab. We found that only a small intralesional injection volume of spesolimab could effectively suppress PPP in this case.
掌跖脓疱病(PPP)是一种慢性病,其特征是手掌和脚底出现无菌性脓疱。众所周知,目前对于这种难治性疾病尚无金标准治疗方法。目前,靶向白细胞介素-36受体(IL-36R)的生物制剂正成为治疗PPP的有前景的方法。在此,我们首次报告了一名接受斯佩索利单抗皮损内注射的中国男性掌跖脓疱病患者。我们发现,在该病例中,仅小剂量皮损内注射斯佩索利单抗就能有效抑制掌跖脓疱病。